Stockscreener 앱 받기
14.20
6.61%
0.88
시장 영업 전:
14.80
0.60
+4.23%
전일 마감가:
$13.32
열려 있는:
$13.99
하루 거래량:
106.10K
Relative Volume:
1.31
시가총액:
$2.43B
수익:
$420.26M
순이익/손실:
$-41.97M
주가수익비율:
-56.80
EPS:
-0.25
순현금흐름:
$-65.34M
1주 성능:
-5.52%
1개월 성능:
-4.44%
6개월 성능:
-25.77%
1년 성능:
-5.52%
1일 변동 폭
$13.79
$14.32
1주일 범위
$13.00
$15.29
52주 변동 폭
$11.93
$21.92
Hutchmed China Limited Adr Stock (HCM) Company Profile
명칭
Hutchmed China Limited Adr
전화
-
주소
-
HCM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HCM
Hutchmed China Limited Adr
|
14.20 | 2.43B | 420.26M | -41.97M | -65.34M | -0.25 |
|
ZTS
Zoetis Inc
|
165.89 | 74.84B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.24 | 41.78B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
12.92 | 40.96B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
21.92 | 24.83B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
143.26 | 14.50B | 2.24B | 385.90M | 440.10M | 3.73 |
Hutchmed China Limited Adr Stock (HCM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-11-24 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2022-05-04 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2021-09-22 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-08-03 | 개시 | Jefferies | Buy |
| 2020-10-02 | 개시 | Deutsche Bank | Buy |
| 2020-03-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-02-20 | 개시 | Goldman | Buy |
| 2019-11-19 | 개시 | CLSA | Buy |
| 2019-10-23 | 재확인 | BofA/Merrill | Buy |
| 2019-07-05 | 개시 | Macquarie | Outperform |
모두보기
Hutchmed China Limited Adr 주식(HCM)의 최신 뉴스
Private equity firms are HUTCHMED (China) Limited's (LON:HCM) biggest owners and were rewarded after market cap rose by UK£120m last week - Yahoo Finance
Hutchmed announces progress, hits milestone with lung cancer treatment - ShareCast
Market news - Research the market
Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million - Benzinga
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy - The Manila Times
HUTCHMED Announces NDA Acceptance in China with Priority - GlobeNewswire
Jane Street Group LLC Raises Stock Holdings in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World
HUTCHMED (China) Limited (NASDAQ:HCM) Shares Purchased by State Street Corp - Defense World
HCMHUTCHMED (China) Limited American Depositary Shares Latest Stock News & Market Updates - StockTitan
HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy - The Manila Times
HUTCHMED Announces Breakthrough Therapy Designation in - GlobeNewswire
HUTCHMEDNew sovleplenib clinical data showcased at ASH - Research Tree
Hutchmed endometrial cancer treatment gets conditional approval in China - ShareCast
M&G Plc Has $5.35 Million Holdings in HUTCHMED (China) Limited (NASDAQ:HCM) - MarketBeat
How Trump and Harris plan to address housing affordability - Yahoo Finance
Blue Trust Inc. Purchases 3,057 Shares of HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World
HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial - Yahoo Finance
HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful - The Bakersfield Californian
HUTCHMED (China) Ltd (HCM) (Q2 2024) Earnings Call Highlights: Strong US Sales Propel Growth ... - Yahoo Finance
FDA Approves 16 New Cancer Treatments As Global Cancer Rates Skyrocket - Barchart
Vanguard Personalized Indexing Management LLC Buys 1,168 Shares of HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World
Rhumbline Advisers Boosts Stock Position in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World
Research Analysts Set Expectations for HUTCHMED (China) Limited’s FY2025 Earnings (NASDAQ:HCM) - Defense World
HUTCHMED (LON:HCM) Share Price Crosses Above 200 Day Moving Average of $284.47 - Defense World
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing - The Manila Times
HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda - Yahoo Finance
CN National Reimbursement Drug List Raises Requirements on Innovative Drugs: Report - AASTOCKS.com
International companies to host live webcasts at Deutsche - GlobeNewswire
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024 - Yahoo Finance
International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024 - Kirkland Lake Northern News
HUTCHMED (China) Limited (NASDAQ:HCM) Shares Sold by Acadian Asset Management LLC - Defense World
HUTCHMED (LON:HCM) Stock Price Crosses Below 200 Day Moving Average of $283.02 - Defense World
HUTCHMED (LON:HCM) Stock Crosses Below 200 Day Moving Average of $281.77 - Defense World
7 Best-Performing China Stocks for October 2024 - NerdWallet
HUTCHMED Voluntarily Withdraws Supplemental New Drug Application in China for Fruquintinib - AASTOCKS.com
HUTCHMED (LON:HCM) Stock Crosses Below Two Hundred Day Moving Average of $280.85 - Defense World
VP Kamala Harris to address Americans at DNC: What to expect - Yahoo Finance
LOBO EV Launches Innovative Solar-Powered Golf Cart to Address Increasing Market Demand for Sustainable Transportation Solutions - Yahoo Finance
HUTCHMED (China) Limited (NASDAQ:HCM) Sees Large Drop in Short Interest - Defense World
HUTCHMED (LON:HCM) Share Price Crosses Above 200-Day Moving Average of $277.00 - Defense World
XPeng Inc. Sponsored ADR (XPEV) Laps the Stock Market: Here's Why - Yahoo Finance
Here is What to Know Beyond Why PDD Holdings Inc. Sponsored ADR (PDD) is a Trending Stock - Yahoo Finance
What Starbucks' new CEO must instantly do to address crisis - Yahoo Finance
Sea Limited (SE) Q2 Earnings Miss Estimates, Revenues Up Y/Y - Yahoo Finance
Here's Why PDD Holdings Inc. Sponsored ADR (PDD) Gained But Lagged the Market Today - Yahoo Finance
Sea Limited (SE) Reportedly Hikes Merchant Fees to Boost Profit - Yahoo Finance
Contrast Security Application Detection and Response (ADR) Praised by Industry Analysts for Addressing Gap in Cybersecurity Defenses - Yahoo Finance
Global Industrial Introduces GlobalPure(TM) PFAS Water Filter to Address Forever Chemicals and Microplastics in Drinking Water - Yahoo Finance
MINISO Group Holding Limited Unsponsored ADR (MNSO) Trades Flat On The Day: What You Should Know - Yahoo Finance
InventHelp Inventor Develops Improved Address Display (CHK-1079) - Yahoo Finance
Sea Limited (SE) to Post Q2 Earnings: What's in the Cards? - Yahoo Finance
Hutchmed China Limited Adr (HCM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.94%
0.08%
자본화:
|
볼륨(24시간):